
# DrSamGirgis.com – insights from a physician blogger

... a blog about medicine, health, wellness, and current events with an emphasis on breaking biomedical news

- About Me
- Ask the Doctor
- Contact
- Disclaimer
- Feedback
- Privacy Policy
- · Terms of Use



Scientists Induce Heart Stem Cells to Repair Damage After a Heart Attack

Blinatumomab Produces Complete Remission in 75% of Adult Acute Lymphoblastic Leukemia Patients

The BRAF V600E Mutation May Cause Molecular Pathogenesis of Hairy Cell Leukemia

Human Eye May Have Sixth Sense of Magnetic Field Sensor

Life In The City Causes Changes In Stress Center of Brain

- « Risk of Second Stroke Is Increased in Patients with Type 2 Diabetes «
- » NFL Quarterback Danny Wuerffel's Malady: What is Guillain-Barre Syndrome? »

Webdesign Berlin

## FDA Joins France and Germany With Actos Bladder Cancer Warning But Stops Short of Recall

Actos (pioglitazone) is a blockbuster diabetes medication produced by the Japanese drug company Takeda Pharmaceuticals. Actos belongs to the thiazolidinedione (TZD) drug class and works by decreasing insulin resistance in type 2 diabetic patients. In the last year, the medication had global sales of \$4.8 billion and accounted for 27% of Takeda's revenue. In 2008, Actos was the tenth best selling medication in the United States. From January 2010 through October 2010, there were an estimated 2.3 million prescriptions filled by diabetic patients that had a pioglitazone containing product from pharmacies in the United States. In preclinical in vivo studies, bladder cancer was observed in male rats receiving clinical equivalent doses of pioglitazone. In addition, two clinical studies of Actos (the PROactive study and a liver safety study) showed a high percentage of bladder cancer cases in patients taking Actos. As a result, the Food and Drug Administration (FDA) has included these findings in the precautions section of the Actos drug label. To address the concerns regarding the possible association with bladder cancer, Takeda is conducting a ten-year observational cohort study and a nested case control study in diabetic patients from the Kaiser Permanente Northern California (KPNC) health plan. Preliminary data from this epidemiological study suggests a possible link between pioglitazone and bladder cancer, and the FDA ordered a safety review in September of 2010. Recently, on June 9, 2011 the French Agency for the Safety of Health Products pulled the product from their market because of safety concerns over the association with bladder cancer. This action was the result of a clinical study conducted by the French National Health Insurance Plan using 1.5 million diabetic patients treated with pioglitazone. It was show that there was a statistically significant increase in the risk for bladder cancer in patients using pioglitazone, and that risk increased with exposure longer than one year. Shortly thereafter, on June 10, 2011 the German Federal Institute for Drugs and Medical Devices advised physicians not to prescribe the medication to their diabetic patients based upon the French data. There have been no other countries that have withdrawn the medication from their markets. At a five-year interim analysis of the KPNC study, the FDA found that there was no significant increase in the risk for bladder cancer in patients taking pioglitazone. However, it was found that the risk for bladder cancer did increase with increasing dose and use longer than one year. Pioglitazone treatment for over 12 months carried a 40% increased risk of bladder cancer. Today, June 15, 2011 the FDA has released a drug safety communication to inform the public of these results. The FDA will include this information on the warnings and precautions section of the drug label. The FDA is recommending that physicians not prescribe pioglitazone to patients with active bladder cancer, and to use caution in patients with a prior history of bladder cancer. The drug was not pulled from the market in the United States. There will be continued analysis of the KPNC data as well as the data from the French study. There will be future updates as additional results are obtained.

Share this:

**Facebook** 

3

**Email** 

Print Share

3

Tags: Actos, bladder cancer, French Agency for the Safety of Health Products, German Federal Institute for Drugs and Medical Devices, Kaiser Permanente Northern California health plan, pioglitazone, Takeda Pharmaceuticals, the PROactive study, type 2 diabetes

This entry was posted on Wednesday, June 15th, 2011 at 6:00 pm and is filed under <u>Uncategorized</u>. You can follow any responses to this entry through the <u>RSS 2.0</u> feed. You can <u>leave a response</u>, or <u>trackback</u> from your own site.

#### 2 Comments

• *Hany S. Girgis* says: June 16, 2011 at 1:48 pm

Pick your poison: diabetes or cancer. Type 2 diabetes is treatable by altering one's lifestyle, but Americans would prefer maintain an unhealthy lifestyle and take a drug that may cause cancer. The FDA understands this preference, otherwise they would have banned Actos in the United States. I presume bladder cancer is curable and is the lesser of the two poisons.

Reply

• Chris Bergstrom says: June 17, 2011 at 8:42 am

Obviously cancer is a terrible disease, but I think it's an oversimplification to say that type 2 diabetes is treatable by altering one's lifestyle. Some cases are, but some cases are not. My grandmother had type 2 diabetes when she got older and was extremely conscientious about her health and eating habits but still required medication. I also want to point out that this is not a story about the FDA coddling Americans too lazy to make lifestyle changes, since no other country besides Germany has withdrawn the drug either.

In short, diabetes is a real disease, which sometimes requires medication. I don't know enough about diabetes to say whether there are other medications available which could be substituted for pioglitazone without the increased cancer risk (if someone knows this I'd be interested to hear their perspective), but if not it may be worth it to keep the medicine available for patients who are informed of the risks and who are without another option to manage their diabetes.

Reply

Leave a Reply		
	Name (required)	
	Mail (will not be published) (required)	
	Website	
Submit Comment		
Notify me of followu	up comments via e-mail	
• 3 • Search for:	Search	
Follow Me O		

#### AdChoices ▷

## **Actos Cancer**

### <u>Lawyers</u>

Lawsuits over Bladder Cancer from Actos are being Reviewed-Learn More www.youhavealawyer.com...

## Actos = Bladder

Cancer?
Bladder Cancer By Diabetes Drug? Call 866-403-0683 For Legal Help! SchneiderWallace.com/Di.

## Stage 4 Cancer

Treatments
Chat w/a Cancer Info Expert About Stage 4 Cancer Treatment Options. www.CancerCenter.com

## **BYETTA**®

BYETTA® (exenatide) injection. View Clinical Trial Data. HCP Info.

### The 30-Day

## **Diabetes Cure**

Type 2 diabetes completely reversed in just 30 days. cure-your-diabetes.com

## Join The Blog

- Register
- Log in
- Entries RSS
- Comments RSS
- WordPress.org

## • Recent Comments

- Dr Sam Girgis on New Advancements Made in the Development of Improved Tuberculosis Vaccine
- Chris Bergstrom on New Advancements Made in the Development of Improved Tuberculosis Vaccine
- Tim Cole on New York City Outlaws Smoking Outdoors as RJ Reynolds Tobacco Company Starts Smokeless Tobacco Ads
- jim snell on Ask the Doctor
- o Dr Sam Girgis on Soy Supplements Do Not Alleviate the Symptoms of Menopause or Aide in Bone Density Preservation

## • Popular Posts

- Hurricane Irene Causes Evacuation of New York City Hospitals in Evacuation Zone A
- o Gene Therapy Modified T Cells Show Strong Response to Chronic Lymphocytic Leukemia Cells
- <u>Did Kate Middleton Use the Dukan Diet To Lose Weight For the Royal Wedding?</u>
- Metastatic Melanoma Patients Receive Two More Treatment Options in Vemurafenib and Ipilimumab
- FDA Joins France and Germany With Actos Bladder Cancer Warning But Stops Short of Recall

Find us on Facebook DrSamGirgis.com Like 49 people like DrSamGirgis.com John Michele Facebook social plugin



• Live Traffic Feed

See your visitors in RealTime! Get the Free Live Traffic Feed Get Feedjit Now!

A visitor from New York arrived from google.com and viewed "Cardiac AAV9-S100A1 Gene Therapy | DrSamGirgis.cominsights from a physician blogger" 9 mins ago

A visitor from Fort Lauderdale, Florida viewed "DrSamGirgis.com - insights from a physician blogger" 16 mins ago

A visitor from Houston, Texas arrived from google.com and viewed

"DrSamGirgis.com -

insights from a physician

blogger" 18 mins ago

A visitor from Philadelphia, Pennsylvania viewed

"Secondhand Smoke Is

Associated With

Free counters



- PRGE RANK 3
- sitemeteralalla
- STAT COUNTER

Sign up for my Free Newsletter!

Email:

Submit

We respect your email privacy

Powered by <u>A Weber email</u> <u>marketing</u>



## Blogroll

- CelebrityDiagnosis.com
- Clinical Cases and Images: CasesBlog 0
- Dr John M
- o drwes.blogspot.com
- Gary Schwitzer's HealthNewsReview Blog
- <u>HealBlog.net</u>
- iMedicalApps.com
- <u>Jay Parkinson + MD + MPH</u>
- KevinMD.com
- Mark's Daily Apple
- Medgadget.com
- Medpedia
- Naturally Selected
- Nature.com NewsBlog
- PharmaTech Talk
- Polite Dissent
- ProBlogger.net

- Respectful Insolence
- Rural Doctoring
- Science-Based Medicine
- sciencebase
- ScienceNow
- ScienceRoll.com
- Stanford Scope Blog
- Suzy Eats
- The Happy Hospitalist
- The White Coat Underground
- Wachter's World

## • Archives



•

Jul »

•

« May







## • Tag Cloud

Affordable Care Act AIDS Alzheimer's dementia atheroslerosis autism autism spectrum disorder beta-amyloid BRAF V600E mutation breast cancer prevention cerebrovascular disease coronary artery disease dementia diabetes diabetes mellitus Dr. Nora D. Volkow Dr. Robert Gallo gene therapy heart attack heart disease high blood pressure hiv HIV vaccine human immunodeficiency virus hypertension Kaiser Permanente Northern California health plan mild cognitive impairment mortality rate NHANES study obesity PAD peripheral artery disease PET imaging schizophrenia sleep disordered breathing smallpox smoking cessation Stroke tobacco addiction type 2 diabetes vaccination vemurafenib World Health Assembly World Health Organization

Copyright © 2011 Dr Sam Girgis MD. All rights reserved. Entries (RSS) and Comments (RSS).



Bad Behavior has blocked 919 access attempts in the last 7 days.

8